Skip to content
ppharmaranks
Menu
Class IIOngoing

Glycopyrrolate Injection recall

FDA recall D-0725-2026 · initiated Jul 16, 2026

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Jul 29, 2026How we research

Fresenius Kabi USA, LLC recalled Glycopyrrolate Injection in Jul 2026 — an FDA Class II recall (D-0725-2026) because Presence of Particulate Matter: Hair was found in product.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Presence of Particulate Matter: Hair was found in product

Something got into the product

A physical or chemical contaminant was found — glass or metal fragments, or a solvent that should not be there.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot #: 6134349, 6134620 Exp. Date 11/2026

Quantity recalled: 59,425 vials

Details

Product
Glycopyrrolate Injection, USP, 1 mg per 5 mL (0.2 mg per mL), 25 x 5 mL fill in a 6.5 mL vial, Rx only, Multiple Dose Vials, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-578-05; NDC Vial: 63323-578-07
Recalling company
Fresenius Kabi USA LLC
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
Nationwide within in the USA
Initiated
Jul 16, 2026
FDA report date
Jul 29, 2026
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Glycopyrrolate Injection recalled?
Fresenius Kabi USA, LLC recalled Glycopyrrolate Injection in Jul 2026 — an FDA Class II recall (D-0725-2026) because Presence of Particulate Matter: Hair was found in product. May cause temporary or medically reversible harm; low probability of serious harm.
Why was Glycopyrrolate Injection recalled?
Per the FDA enforcement record, the reason for recall D-0725-2026 was: Presence of Particulate Matter: Hair was found in product
Is a recalled Glycopyrrolate Injection dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Glycopyrrolate Injection are affected?
Distributed: Nationwide within in the USA. The recall covers these lots — Lot #: 6134349, 6134620 Exp. Date 11/2026. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0725-2026.

Source: openFDA Drug Enforcement record D-0725-2026

← All drug recalls